EVALUATION OF THE EFFECT OF ANGICO POLYSACCHARID Anadenanthera colubrina (Vell.) IN EXPERIMENTAL MODEL OF INTESTINAL MUCOSITE INDUCED BY 5‐FLUOROURACILIL IN MICE
Authors: Pimenta Helder Bindá , de Carvalho Vale Larice , Barbosa Maria Lucianny Lima , Silva Durcilene Alves da , Medeiros Jand Venes Rolim , Cerqueira Gilberto Santos 
Published: June 2021

Intestinal mucositis (MI), characterized by inflammation and ulceration of the intestinal mucosa, is one of the main causes of morbidity and mortality in chemotherapy patients (LEE et al., 2014).

GOALS

To evaluate the action of the white angico polysaccharide on the histological changes in villi and crypts induced by 5‐FU in the intestinal mucosa;

To verify the role of the white angico polysaccharide in the involvement of the cyclooxygenase‐2 (COX‐2) pathway in the 5‐FU induced intestinal mucositis model;

METHODS

The experimental protocol was forwarded and approved by the Ethics Committee for Animal Use (CEUA) of UFC (3463140518). Intestinal mucositis was induced in mice with administration of 5‐FU, according to the methodology described by Carneiro‐Filho et al. (2004), in which the mice received on the first day of the experiment a single dose of 5‐FU (450 mg/kg) via intraperitoneal (i.p). The treatment was done using three doses of the white angico polysaccharide (100, 200, 400 mg/kg) one day after the injection of 5‐FU, the doses being based on Santos et al. (2013). The animals were divided into groups:

Group I (Saline): saline solution 0.9% (0.1 mL/10g) and intraperitoneal (i.p), in parallel to the other groups treated throughout the study.

Group II (5‐FU): on the first day of the experimental protocol will receive a single dose of 5‐FU (450 mg/kg) i.p. and will be treated with 0.9% saline solution (0.1 mL/10g) on the next four days.

Group III (Angico best dose): 5‐FU (450 mg/kg) i.p on the first day of the experiment and was treated with angico diluted in distilled water.

Group IV (Celecoxib): single dose of 5‐FU (450mg/kg) intraperitoneally (i.p) on the first day. On the following days of the experimental protocol only Celecoxib (7.5 mg/kg, i.p) was administered

Group V (Celocoxib + Angico best dose): single dose of 5‐FU (450mg/kg) intraperitoneally (i.p) on the first day. On the second day of protocol, they was received white angico polysaccharide diluted in distilled water, and Celecoxib (7.5 mg/kg, i.p).

After the histological processing, the morphometric evaluation was carried out with the aid of the ImageJ software, where the height of the villi and the depth of the crypts were measured. Immunohistochemistry for COX‐2 was then performed using the streptavidin‐biotin‐peroxidase method (HSU; RAINE, 1981)R

RESULTS

The white Angico polysaccharide was able to statistically (p <0.05) prevent the shortening of villi and decrease the depth of the crypts caused by 5‐FU (Figure 1). The groups treated with angio 400 mg/kg, CLX and the CLX + angio combination (Figure 2) showed a statistically significant (p <0.05) reduction of the immunolabelled area for COX‐2 when compared to the 5‐FU group.

CONCLUSION

The white angico polysaccharide protected the intestinal mucosa and promoted a decrease in COX‐2 expression in the 5‐FU induced intestinal mucositis model.

This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.